New drug goals for heart failure

An innovative study at Cardiovascular research of nature It reveals the promises to goals for heart failure (HF) and its subtypes, offering new hope for precision medicine in cardiology.

Study: Large -scale multi -group identifies drug goals for heart failure with reduced and preserved extrusion fraction. Credit Picture: Owlie Productions / Shutterstock.com

A recent study published in Cardiovascular research of nature It identifies several promising targets of heart failure (HF) and clinical subtypes.

HF treatment and its subtypes

With each heartbeat, the heart draws 50-70% of the volume of blood in the left ventricle in other organs throughout the body, which is otherwise known as the left-handed abdominal abdominal volume (LVEF).

LVEF is used to sort the clinical subtypes of HF. While HF with a reduced extrusion fraction (HFREF) occurs when a person’s LVEF is less than or equal to 40%, the HF with an extrusion fraction (HFPEF) occurs when LVEF is greater than or equal to 50%.

Current estimates show that about 64 million people around the world are diagnosed with HF. Despite the availability of many HF therapeutic therapeutic, some of which include aldosterone competitors, beta inhibitors and diuretics, most available treatments, except for glucose 2 (SGLT-2) inhibitors. .

For the study

In the current study, researchers use a combination of human genetic, protein and transcriptional data to identify potential drug goals for HF and its clinical subtypes. Mendelian Randomization (MR) was used to detect proteins that are causally associated with the development of HFPEF and HFREF.

MR is a statistical method used to evaluate the causal effects of risk factors on human biology and diseases. In particular, this approach uses genetic variations of a certain risk factor to determine the causal impact of this risk factor on disease development. Since genetic variants are accidentally inherited by parents to their children, they are probably not likely to be associated with confusion.

In the current study, it was systematically applied MR to data received from 27,799 HFREF and 25,579 HFPEF patients in three large cocktails, including Fenland, Decoding and Atherosclerosis Risks in Communities (ARIC). A total of 4,988 unique human proteins from these specimens were measured and associated with genetic variations associated with the levels of these proteins.

For each gene that was significantly associated with either the HF clinical subtype, a therapeutic target profile was designed which also considered the therapeutic efficacy, the safety of the target, the innovation of the biological mechanism, the pharmaceuticality and the projected mechanism of action of the gene. This profile was backed by data from Knockout Pontic Models, supposed variants of operating loss by the UK Biobank, and magnetic resonance imaging parameters (MRI).

Study findings

The MR resolution led to the identification of 70 and 10 target genes for HFRF and HFPEF, respectively, 49 and nine of which have never been mentioned before. Some of the well -known cardiomyopathy genes found included alpha 2 (Actn2), Filamin C (FLNC), Ras as without caax 1 (Rit1) and Delta Sarcoglycan (Sgcd).

Several quality control steps were incorporated into the analysis to ensure that the MR findings were strong and were not affected by certain confusing factors such as connection imbalance or weak bias. For example, 42 genes showed strong signs of co-adoption, thus suggesting any lesions in the expression of these genes that may contribute to the risk of HF.

We have identified many genes as reasonable targets for HFREF and HFPEF and found elements from rectangular sources to support their effectiveness and inform about the mechanism of action required for a therapeutic solution. “

Mtss1

Mtss1 Codings for metastasis 1, a cytoskeletal protein involved in maintaining cellular structure and immigration. Many studies have reported the repressive action of the volume of Mtss1; However, more recent evidence shows that this gene may also be involved in certain cardiovascular disease.

In the current study, the increased expression of the Angelophorous Rivonuclein Acid (MRNA) cis-The productive RS7461129/Mtss1 In the left ventricle it increases the risk of HFREF. Ten CMR finds of the left and right ventricle were also identified, nine of which were directly related to HFref findings.

Overall, these findings suggest that the suspension of Mtss1 It has the ability to be therapeutically effective against HF, especially HFREF, and justifies additional research.

Zbtb17

Zinc finger and BTB containing field 17 (Zbtb17) encodes the transcription factor of the zinc finger and the BTB/POZ (ZBTB) family involved in gene regulation and cell differentiation. In the present study, Zbtb17 had a strong MR correlation with HFREF and increased significantly in the left ventricle, thus indicating the potential role of a Zbtb17 Inhibitor in future drug discovery studies.

Nfatc2ip

Nuclear factor of activated T-cells, cytoplasmic 2 interacting protein (Nfatc2ip) Regulates the activity of the nuclear factor of activated T-cells (NFAT) proteins, which are involved in the activation of T-cells, the production of cytokines and other pathways of immunological signaling.

In the present study, Nfatc2ip It was associated with an increased risk of HFPEF and a larger mass of the left ventricle. In addition, the relationship between Nfatc2ip And an increased risk of HFPEF was associated with various HF features of HF, some of which include high levels of systolic blood pressure (BP), C-reactive protein levels (CRP) and Body Mass Index (BMI).

Conclusions

Other genes resulting as potential drug targets for HFREF include interleukin-6 receptor (Il6R), adrenomedullin (Branded) and the type of endothelin receptor (Ednra), while lipoprotein (a) (LPA) appeared as a target for both HFREF and HFPEF. Some of the main advantages of the current study include the large number of HFREF and HFPEF cases, as well as the use of multiple rectangular approaches, to confirm causal relationships between the risk of HF and the targets of proteins with drugs.